CSL Calls Off Talecris Biotherapeutics Merger

WASHINGTON (CN) - CSL Limited will not proceed with its proposed $3.1 billion acquisition of Talecris Biotherapeutics, CSL said Monday. The Federal Trade Commission went to court to block the merger, claiming it would reduce competition in the U.S. markets for four plasma-derivative protein therapies - Immune globulin, Albumin, Rho-D, and Alpha-1.

The therapies are used to treat patients suffering from illnesses such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, alpha-1 antitrypsin disease, and hemolytic disease of the newborn.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit